<unk>  (marketed under brand name Doxans) is a benzodiazepine derivative drug developed by Schiapparelli in the 1970s. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. It is used therapeutically as a hypnotic. According to Babbini and colleagues in 1975, this derivative of flurazepam was between 2 and 4 times more potent than the latter while at the same time being half as toxic in laboratory animals. Section 5.5 of the article<unk>  in volume 66 of the World Health Organization's (WHO) and International Agency for Research on Cancer's (IARC) IARC Monographs On The Evaluation Of Carcinogenic Risks To Humans, an article describing the carcinogenic/toxic effects of<unk>  on humans and experimental animals, states that there is "inadequate evidence in humans for the carcinogenicity of<unk> " and limited evidence in experimental for the carcinogenicity of<unk> ," and concluded that the overall evaluation of the substance's carcinogenicity to humans is "not classifiable."
Doxefazepam
Oxazepam
Halazepam
Triazolam
Quazepam
Cinolazepam
Medazepam
Climazolam